|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2912-2919.
Prepublished online as a Blood First Edition Paper on June 30, 2005; DOI 10.1182/blood-2005-05-2004.
 Previous Article | Next Article 
Submitted May 19, 2005
Accepted June 16, 2005
Hematopoietic cell transplantation-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
Mohamed L Sorror, Michael B Maris, Rainer Storb*, Frederic Baron, Brenda M Sandmaier, David G Maloney, and Barry Storer
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; University of Washington, Seattle, Washington, USA
* Corresponding author; email: rstorb{at}fhcrc.org, blarson@fhcrc.org.
We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT). However, the sample size of patients with scores of  1, captured by the CCI, did not exceed 35%. Further, some comorbidities were rarely found among patients given HCT. Therefore, the current study was designed to a) better define previously identified comorbidities utilizing pretransplant laboratory data, b) investigate additional HCT-related comorbidities, and c) establish comorbidity scores that were suited for HCT. Data were collected from 1055 patients, and then randomly divided into training and validation sets. Weights were assigned to individual comorbidities according to their prognostic significance in Cox proportional hazard models. The new index was then validated. The new index proved to be more sensitive than the CCI since it captured 62% of patients with scores >0 compared to 13%, respectively. Further, the new index showed better survival prediction (likelihood ratio of 23.7 versus 7.1 and c statistics of 0.661 versus 0.561, P=< 0.0001, respectively). In conclusion, the new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted non-relapse mortality and survival. This index will be useful for clinical trials and patient counseling before HCT.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
HCT outcomes: a new tool?
- Roy B. Jones
Blood 2005 106: 2602-2603.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
E. Jantunen, C. Canals, A. Rambaldi, G. Ossenkoppele, B. Allione, D. Blaise, E. Conde, H. Tilly, G. Cook, F. Clark, et al.
Autologous stem cell transplantation in elderly patients (>=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry
Haematologica,
December 1, 2008;
93(12):
1837 - 1842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-V. Malfuson, A. Etienne, P. Turlure, T. de Revel, X. Thomas, N. Contentin, C. Terre, S. Rigaudeau, D. Bordessoule, N. Vey, et al.
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
Haematologica,
December 1, 2008;
93(12):
1806 - 1813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hosing, R. M. Saliba, G.-J. Okoroji, U. Popat, D. Couriel, T. Ali, L. De Padua Silva, P. Kebriaei, A. Alousi, M. De Lima, et al.
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age
Ann. Onc.,
June 1, 2008;
19(6):
1166 - 1171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Rezvani, B. Storer, M. Maris, M. L. Sorror, E. Agura, R. T. Maziarz, J. C. Wade, T. Chauncey, S. J. Forman, T. Lange, et al.
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 10, 2008;
26(2):
211 - 217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Baer, H. D. Klepin, and A. S. Artz
Acute Leukemia in Older Adults: Are We Treating Too Much or Too Little?
ASCO Educational Book,
January 1, 2008;
2008(1):
216 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
Blood,
January 1, 2008;
111(1):
446 - 452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Sorror, S. Giralt, B. M. Sandmaier, M. De Lima, M. Shahjahan, D. G. Maloney, H. J. Deeg, F. R. Appelbaum, B. Storer, and R. Storb
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
Blood,
December 15, 2007;
110(13):
4606 - 4613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Brunstein, J. N. Barker, D. J. Weisdorf, T. E. DeFor, J. S. Miller, B. R. Blazar, P. B. McGlave, and J. E. Wagner
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
Blood,
October 15, 2007;
110(8):
3064 - 3070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb
Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation
J. Clin. Oncol.,
September 20, 2007;
25(27):
4246 - 4254.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Blaise, N. Vey, C. Faucher, and M. Mohty
Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia
Haematologica,
April 1, 2007;
92(4):
533 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al.
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
J. Clin. Oncol.,
January 1, 2007;
25(1):
25 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Antin
Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2
Hematology,
January 1, 2007;
2007(1):
47 - 54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sorror, B. M. Sandmaier, B. Storer, M. B. Maris, D. G. Maloney, and R. Storb
Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
550 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Giles, G. Borthakur, F. Ravandi, S. Faderl, S. Verstovsek, S. Pierce, E. Jabbour, J. Cortes, and H. Kantarjian
Comorbidity Scoring Using the Hematopoetic Cell Transplantation Comorbidity Index (HCTCI) Is Predictive of Early Death Rate and Event Free Survival (EFS) in Patients over 60 Years of Age Receiving Induction Therapy for Acute Myeloid Leukemia (AML).
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
1975 - 1975.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Abdalla, K. A. Guthrie, M. L. Sorror, and M. Linenberger
Apheresis Safety and Product Yield among Elderly Donors for Allogeneic Sibling Hematopoietic Cell Transplantation (HCT).
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
5223 - 5223.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Baron, R. Storb, B. E. Storer, M. B. Maris, D. Niederwieser, J. A. Shizuru, T. R. Chauncey, B. Bruno, S. J. Forman, P. A. McSweeney, et al.
Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation
J. Clin. Oncol.,
September 1, 2006;
24(25):
4150 - 4157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Parimon, D. H. Au, P. J. Martin, and J. W. Chien
A risk score for mortality after allogeneic hematopoietic cell transplantation.
Ann Intern Med,
March 21, 2006;
144(6):
407 - 414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Scott and B. M. Sandmaier
Outcomes with Myeloid Malignancies
Hematology,
January 1, 2006;
2006(1):
381 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
